- In late July 2026, Alnylam Pharmaceuticals cut its full-year TTR product sales guidance after reassessing growth expectations for the ATTR-CM market, prompting a law firm to continue investigating potential federal securities law violations related to the company’s disclosures.
- This combination of lowered product expectations and legal scrutiny may influence how investors view the resilience and risks of Alnylam’s RNAi-focused business model.
- We’ll now examine how the reduced TTR sales guidance, especially tied to ATTR-CM market expectations, may reshape Alnylam’s investment narrative.
Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
Alnylam Pharmaceuticals Investment Narrative Recap
To own Alnylam, you need to believe its RNAi platform and TTR franchise can support durable revenues despite pricing, margin and concentration pressures. The cut to 2026 TTR sales guidance and ongoing legal investigation both touch the current core risk: dependence on ATTR-CM expectations and related disclosures. For now, these developments highlight uncertainty around near term TTR growth but do not clearly displace the TTR franchise as the main driver of the story.
The most relevant recent announcement here is the July 30 guidance update, where Alnylam trimmed net product revenue expectations to US$4,700 million to US$5,100 million for 2026. That change directly reflects softer ATTR-CM growth assumptions and frames how sensitive the business is to TTR demand. As investors weigh catalysts like further clinical data or payer decisions, this reset in guidance is now a key reference point for judging whether Alnylam can support its current valuation.
Yet behind Alnylam’s RNAi promise, the concentration in TTR and fresh legal and pricing questions is something investors should be aware of...
Read the full narrative on Alnylam Pharmaceuticals (it's free!)
Alnylam Pharmaceuticals' narrative projects $9.0 billion revenue and $2.0 billion earnings by 2029.
Uncover how Alnylam Pharmaceuticals' forecasts yield a $434.72 fair value, a 89% upside to its current price.
Exploring Other Perspectives
Before this setback, the most optimistic analysts were modeling about US$10.9 billion in 2029 revenue and US$2.9 billion in earnings, which contrasts sharply with today’s TTR guidance cut and shows how far expectations can swing.
Explore 5 other fair value estimates on Alnylam Pharmaceuticals - why the stock might be worth just $305.63!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Alnylam Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alnylam Pharmaceuticals' overall financial health at a glance.
Want Some Alternatives?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
- The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com